WASHINGTON (Reuters) - The U.S. Food and Drug Administration
on Friday approved a cheaper, biosimilar version of AbbVie's
top-selling arthritis drug, Humira.

The drug, Amjevita, known also as adalimumab-atto, is made
by biotechnology company Amgen Inc and was approved to treat
rheumatoid arthritis, psoriatic arthritis, Crohn's disease,
psoriasis and other conditions.

Amjevita is the fourth biosimilar to be approved by the FDA.
Last month it approved Novartis AG's biosimilar version of
Amgen's arthritis drug, Enbrel (etanercept).